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https:/WHAT THIS PAPER ADDS
This is the first scoping review of the literature focusing on how the clinical practice guidelines on acute limb
ischaemia (ALI) may need to be adapted as a result of the COVID-19 pandemic. It is important to optimise the
care of patients suffering from both COVID-19 and ALI.Objective: To perform a scoping review of how patients with COVID-19 are affected by acute limb ischaemia (ALI)
and evaluate the recommendations of the 2020 ESVS ALI Guidelines for these patients.
Methods: Research questions were defined, and a systematic literature search was performed following the
PRISMA guidelines. Abstracts and unpublished literature were not included. The definition of ALI in this
review is in accordance with the ESVS guidelines.
Results: Most identified papers were case reports or case series, although population based data and data from
randomised controlled trials were also identified. In total, 114 unique and relevant papers were retrieved. Data
were conflicting concerning whether the incidence of ALI increased, or remained unchanged, during the
pandemic. Case reports and series reported ALI in patients who were younger and healthier than usual, with
a greater proportion affecting the upper limb. Whether or not this is coincidental remains uncertain. The
proportion of men/women affected seems unchanged. Most reported cases were in hospitalised patients with
severe COVID-19. Patients with ALI as their first manifestation of COVID-19 were reported. Patients with ALI
have a worse outcome if they have a simultaneous COVID-19 infection. High levels of D-dimer may predict
the occurrence of arterial thromboembolic events in patients with COVID-19. Heparin resistance was
observed. Anticoagulation should be given to hospitalised COVID-19 patients in prophylactic dosage. Most of
the treatment recommendations from the ESVS Guidelines remained relevant, but the following were
modified regarding patients with COVID-19 and ALI: 1) CTA imaging before revascularisation should include
the entire aorta and iliac arteries; 2) there should be a high index of suspicion, early testing for COVID-19
infection and protective measures are advised; and 3) there should be preferential use of local or
locoregional anaesthesia during revascularisation.
Conclusion: Although the epidemiology of ALI has changed during the pandemic, the recommendations of the
ESVS ALI Guidelines remain valid. The above mentioned minor modifications should be considered in patients
with COVID-19 and ALI.responding author. Department of Vascular Surgery, Amsterdam UMC, location AMC, Meibergdreef 9, P.O. Box 22660, Amsterdam, 1100 DD, the Nether-
-mail address: v.jongkind@amsterdamumc.nl (Vincent Jongkind).
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license (http://creativecommons.org/licenses/by/4.0/).Table 1. Pre-defined questions for a literature search of how
patients with COVID-19 are affected by acute limb
ischaemia (ALI)
Section Specific questions
Epidemiology Are there indications that the number of
patients treated for ALI has increased during
the pandemic?
Has the age and sex of the patients treated
changed?
Has the proportion of upper and lower limb
ischaemia changed?
The proportion of embolus vs. thrombosis?
Has the number of simultaneous venous and
arterial thromboses changed?
Is the outcome of ALI in patients infected withINTRODUCTION
In February 2020 the European Society for Vascular Surgery
(ESVS) 2020 Clinical Practice Guidelines on the Manage-
ment of Acute Limb Ischaemia (ALI) were published.1 They
were the first ever guidelines to be published focusing on
how to treat patients with ALI, irrespective of aetiology. The
publication of this document coincided with the start of the
COVID-19 pandemic, and was timely, as both venous and
arterial thrombosis have been recognised as important
manifestations of the disease.2,3 In April 2020 the editors of
this journal made an early call for research initiatives linked
to the pandemic.4 One important question is whether the
diagnostic and management recommendations issued in
the ALI Guidelines are applicable to a patient who develops
ALI as a manifestation of COVID-19, or if the recommen-
dations require adjustment. It is also important to try to
understand how the pandemic has affected the epidemi-
ology of ALI. It was difficult for the writing committee (WC)
to perform this analysis at the very beginning of the
pandemic, as there were simply not enough data, and only
personal observations and case reports were available.
Most of the members of the ALI Guidelines WC agreed
to perform a scoping review to address this issue, and it
was completed in July 2021. The aim of the scoping re-
view was to determine the extent of research performed
on how patients with COVID-19 infection are affected by
ALI, summarise the findings, identify knowledge gaps,
and evaluate whether specific recommendations of the
2020 ESVS ALI Guidelines need to be modified for the
diagnosis and management of this new and large patient
group.COVID-19 different from other forms of ALI?
Pathophysiology Is there a specific pathophysiology of ALI in
patients infected with COVID-19?
Are there results from pathology investigations
in patients infected with COVID-19 with ALI?
Are synchronous multifocal occlusions
common?
Diagnosis Is computed tomography angiography still the
first choice imaging modality?
Any new biomarkers that have been used in
patients infected with COVID-19?
Initial
management
Should intravenous heparin be administered as
initial management?
Open surgery Has the proportion treated by open and
endovascular surgery changed?
Are there specific reasons to primarily choose
open or endovascular surgery?
Thrombolysis Is there a need for systemic heparinisation
during thrombolysis considering an increased
thrombogenicity?
Is enhancement of thrombolysis with
percutaneous mechanical thrombectomy
beneficial?
Other Is intensified follow up required?
Are there data on best anticoagulation
postintervention?METHODS
A scoping review was performed according to PRISMA
Protocols Extension for Scoping Reviews.5 A systematic
search strategy was used. A literature search of articles in
the PubMed and EMBASE databases was performed up to
22 June 2021. The following search terms were used:
COVID-19, corona virus, coronavirus, SARS-COV2, acute limb
ischaemia. No limitations were used. Reference checking
and manual searching by the members of the WC added
other relevant literature. Only full text original articles
published in peer reviewed journals were considered
eligible. Abstracts and unpublished literature were
excluded. The definition of ALI in the published guidelines1
was the following: “ALI is characterised by a sudden
decrease in arterial perfusion of the limb, with a potential
threat to limb survival, requiring urgent evaluation and
management. ALI is considered when the symptom dura-
tion is less than two weeks”. In this review, ALI was
considered to be associated with COVID-19 infection when
the event occurred within 30 days from the onset of thecite this article as: Jongkind V et al., Update of the European Society for Vas
Limb Ischaemia in Light of the COVID-19 Pandemic, Based on a Scoping Rev
//doi.org/10.1016/j.ejvs.2021.08.028COVID-19 infection, or during a hospital stay for COVID-19
infection. Also considered was any ALI occurring within 30
days of vaccination to prevent COVID-19. In clinical practice
it is sometimes uncertain which event occurred first, the
COVID-19 infection or the ALI, and this can be dependent
on the frequency and sensitivity of testing for COVID-19.
With this 30 day limit for association between the two
events, however, the definition is inclusive. Any studies
describing patients with ALI that could be associated with
COVID-19 infection were included. Also, studies describing
the effect of the COVID-19 pandemic on care for patients
with ALI were included. Narrative reviews and editorials
were excluded, as were studies describing only venous
thrombosis or chronic limb threatening ischaemia.
Screening of abstracts and selection based on full text re-
view was performed by two authors (VJ, AS). Apart from thecular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of
iew of the Literature, European Journal of Vascular and Endovascular Surgery,
Scoping Review: Acute Limb Ischaemia in Patients with COVID-19 3systematic search, manual searching by the members of the
WC retrieved additional studies.
Specific research questions were defined by consensus
among the WC prior to the systematic search (Table 1) and
divided between the authors in groups of two or three
persons who read the selected manuscripts considering
their specific research question. The results were then
communicated within the entire group of authors. Accord-
ing to methodology for scoping reviews, a descriptive
narrative of the data is presented and no data analysis is
performed.6
RESULTS
The search strategy identified 226 studies. Some 53 studies
were excluded based on title and abstract. After reading full
texts, 114 studies were included in the review (Fig. 1). There
were 89 case reports or small series (n < 10), one rando-
mised controlled trial (RCT), three systematic reviews, and
nine cohort studies reporting on 13 e 49 patients with ALI
associated with COVID-19. Other included studies included
cohort studies only on incidence or mortality of ALI asso-
ciated with COVID-19, or review of organisation of care for
ALI during the pandemic. A complete reference list of all
included studies is presented in Appendix A. No studies
were identified reporting ALI in patients after receiving
vaccination to prevent COVID-19.Pathophysiology
In patients with pre-existing peripheral arterial disease
(PAD), it may be difficult to ascertain whether the cause ofRecords identified from PubMed (n = 105)
and Embase databases (n = 156)  
Records screened after removing
duplicates (n = 177) 
Records excluded (n = 53)
Reports assessed for eligibility (n = 124)
Reports excluded:
 Narrative review (n = 6)
 No ALI (n = 15)
 Editorial (n = 5)
 Full text not retrievable (n = 
 Abstract only (n = 7)
 Letter to the editor (n = 8) 
Studies included in review (n = 114)
























Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-A
with COVID-19 are affected by acute limb ischaemia (ALI).
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https://doi.org/10.1016/j.ejvs.2021.08.028ALI was related to a “normal” atherosclerotic process, or if
it was influenced or precipitated by the presence of COVID-
19. The pathophysiology of COVID-19 associated ALI is
multifactorial and not yet fully understood. Coagulopathy,
hyperinflammation, and endothelial injury play a role,
leading to micro- and macrovascular thrombosis.7e9 Endo-
thelial injury and infiltration by inflammatory cells can occur
in previously healthy endothelium. In pathology specimens
after major amputation following COVID-19 associated ALI
in patients without a history of peripheral arterial disease,
inflammation of the endothelium with small vessel
congestion was found.10 There are multiple case reports of
COVID-19 associated ALI in patients without known pe-
ripheral arterial disease, and even in young patients without
comorbidities or atherosclerosis.11e15
Coagulopathy is most apparent in hospitalised patients
with severe COVID-19 infection, but COVID-19 associated
ALI is also reported in patients with mild COVID-19 symp-
toms recovering at home.14e17 Patients may present with
ALI as their first manifestation of COVID-19 infection.15,18,19
Two case reports reported that ALI may occur in patients
with mild symptoms of COVID-19, and in individuals who
are otherwise asymptomatic or have no respiratory
symptoms.20,21
Epidemiology
The first research questions focused on how the epidemi-
ology of ALI may have changed during the pandemic. The
data on the number of patients being treated with ALI
during the COVID-19 pandemic are heterogeneous and
conflicting. This is hardly surprising given that the number2)
Records identified from:
 Citation searching (n = 49)
Reports excluded:
 No ALI (n = 6)
 Narrative
  review (n = 4)
 Editorial (n = 4)
 Letter to the
  editor (n = 2)
Identification of studies via other methods
nalyses (PRISMA) flow diagram of literature search of how patients
cular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of
iew of the Literature, European Journal of Vascular and Endovascular Surgery,
4 Vincent Jongkind et al.of patients with ALI presenting to vascular surgeons is likely
to be influenced by the phase of the pandemic, local COVID-
19 prevalence rates, public health and specialty guidelines
in surgery and vascular surgery, as well as the availability of
local resources.
Data from the US and Italy suggested that the pandemic
had a major impact on the delivery of vascular services in
general.22e24 In Italy when resources were particularly
stretched during the first wave, ALI was the most frequent
presentation of peripheral vascular disease requiring surgi-
cal treatment.24 In contrast, the proportions of patients
receiving operations for acute and chronic limb ischaemia in
Sweden were unchanged in 2020 compared with the period
2017 e 2019.26 The numbers of patients admitted to hos-
pital in Germany with acute limb ischaemia declined by 12%
from the pre-COVID-19 period (January e May 2019) to
January e May 2020 (5.1 e 4.6 per 100 000 insured
patients).27
Potential concerns were raised early in the pandemic
among vascular surgeons that a reduction in elective sur-
gical capacity and treatment, combined with delayed pre-
sentations may increase the rates and severity of ALI.
However, data from Portugal suggest that there was no
evidence that patients presented later with more advanced
ALI during the early part of the pandemic.28
The incidence of ALI in patients who are admitted to
hospital with mild symptoms from COVID-19 is relatively
low: 0.4% e 0.9%.19,29e32 In critically ill patients who need
intensive care it is higher. In a systematic review of five
cohort studies, the prevalence of ALI was 2.5% (58% of all
arterial thromboses) in patients critically ill with COVID-19.7
Similar incidences of ALI in critically ill patients who were
treated with prophylactic or therapeutic anticoagulation
were found by (multicentre) studies from France and Italy:
0.6%,33 2.2%,34 and 2.4%.16
Another important question is whether there has been a
change in demographics of ALI as a result of COVID-19,
namely age, sex, and ethnic background. Most of the pa-
tients presenting with ALI and COVID-19 were men, elderly
(aged > 60 years), and had co-morbidities.7 Similar sex
distributions were identified in Turkey30 (16.7% women)
and Peru18 (23.3% women), with most patients being men,
elderly, and with significant comorbidities. Nevertheless,
there are several reports of ALI in patients suffering from
COVID-19 who have no known peripheral arterial disease,
and even in young patients without comorbidities or sig-
nificant pre-existing atherosclerosis.4,11e15,30 Although
these reports do exist, suggesting the existence of a new
group with ALI, there are no large population based studies
that can verify this observation.
Some studies highlighted that a significant proportion
(12% e 18%) of patients have evidence of thrombus in
multiple arterial locations including the aorta, visceral ar-
teries, cerebral arteries, coronary arteries, but that most are
located in the lower limb.7,11,12,17,19 The present review didPlease cite this article as: Jongkind V et al., Update of the European Society for Vas
Acute Limb Ischaemia in Light of the COVID-19 Pandemic, Based on a Scoping Rev
https://doi.org/10.1016/j.ejvs.2021.08.028not find data on the proportion of embolus vs. thrombosis
in patients with ALI.
Although the focus of this review was arterial thrombosis
and embolism leading to ALI, an increased tendency of
simultaneous venous and arterial thrombosis could affect
the outcome of ALI. Some patients with COVID-19 develop
a generalised pro-thrombotic state and may suffer
concomitant arterial and venous thrombosis. In one study,
16% of patients with ALI were found to have a concomitant
deep vein thrombosis.19
Diagnosis and imaging
The 2020 ALI guidelines recommended preferential use of
computed tomography angiography (CTA) when imaging
patients with ALI, because of its availability and usefulness
for planning treatment.1 Although the recommendations
did not specifically mention that CTA should include the
entire vascular tree (from the supra-aortic trunks to the
feet), in most centres complete imaging is actually per-
formed. In patients with COVID-19 presenting with lower
limb ALI, however, there is often anatomically more
extensive disease, and a greater clot burden, with
concomitantly higher rates of amputation.34 For this reason,
it is recommended that complete imaging with CTA from
aortic arch to the feet/hands should be used in these pa-
tients. The latter also allows exclusion of other thrombo-
embolic events such as pulmonary thromboembolism,
cardiac thrombi, and aortic thrombus that have been re-
ported to occur relatively often in combination with lower
limb ALI in patients with COVID-19.7
Laboratory tests
Global haemostatic tests (e.g., thrombo-elastography and
clot wave analysis) may be useful in early identification of
hypercoagulable states leading to thromboembolic
events.35e38 Laboratory coagulation monitoring (D-dimer,
prothrombin time, fibrinogen and platelet count) might
identify patients at increased thrombotic risk, and/or who
are in a hypercoagulable state or even disseminated intra-
vascular coagulation.39 A high level of D-dimer (the exact
levels depend on the laboratory method used) might have
predictive value for the occurrence of arterial thrombo-
embolic events in patients with COVID-19.40,41
Prophylactic anticoagulation
Patients with COVID-19 may have abnormal coagulation
patterns interfering with adequate therapeutic anti-
coagulation; ALI may even occur in critically ill patients
suffering from COVID-19, despite receiving anticoagulation
at prophylactic or therapeutic dosages.16,33,34 Multiple
studies are currently being performed to identify the best
prophylactic anticoagulation strategy for (subgroups of)
patients with COVID-19. In one randomised controlled trial
(RCT) from Brazil, 615 patients with COVID-19 and elevatedcular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of
iew of the Literature, European Journal of Vascular and Endovascular Surgery,
Scoping Review: Acute Limb Ischaemia in Patients with COVID-19 5D-dimer levels were studied to evaluate the potential
benefit of therapeutic (vs. prophylactic) anticoagulation in
this subgroup of patients considered to be at higher risk of
thrombotic events.32 No difference was found in the com-
posite thrombotic outcome (7% vs. 10%, p ¼ .32), but
bleeding complications increased (8% vs. 2%, p ¼ .001).
There was only one patient who developed ALI in the study.
Another multicentre RCT from Iran on 600 patients found
no benefit of intermediate dose vs. standard dose prophy-
lactic anticoagulation among patients with COVID-19
admitted to the intensive care unit (ICU).42 A systematic
review with meta-analysis on cohort studies was published
showing benefit for prophylactic anticoagulation over no
anticoagulation.43 Anticoagulation at therapeutic dose
might benefit some subgroups, but also increases the risk of
bleeding.Initial management and referral
Initial management of patients with ALI during the COVID-
19 pandemic is similar, and the recommendations in the
guidelines (9e14) are still valid: adequate analgesia, intra-
venous rehydration, supplementary oxygen, and intrave-
nous heparin.1 As discussed under Diagnosis, some patients
present with ALI as their first symptom of COVID-19 infec-
tion. Thus, a high index of suspicion, early testing for COVID-
19 infection, and protective measures are advised for all
patients presenting with ALI during the pandemic.
Timely review by a vascular specialist remains critical in
the management of patients with COVID-19 and ALI.44
Therapeutic anticoagulation with intravenous unfractio-
nated heparin (bolus followed by continuous infusion)
should be provided once a diagnosis of ALI is established,
unless there are significant contraindications such as active
or serious bleeding in the previous 24 e 48 hours, or recent
surgery. This is similar to Recommendation #9 in the ALI
Guidelines, but the importance of early heparinisation is
underlined during the pandemic. In addition, patients with
COVID-19 may have abnormal coagulation patterns inter-
fering with adequate therapeutic anticoagulation: heparin
resistance, which is rare overall, has been observed among
COVID-19 patients, although the exact incidence is uncer-
tain.41 Early and frequent assessment of APTT, activated
clotting time or factor anti Xa levels can be of value.
Currently, there are no data suggesting superiority of any
form of anticoagulation: unfractionated heparin, low mo-
lecular weight heparin, or direct oral anticoagulants.43Decision making
Based on a patient’s overall clinical presentation, a decision
is needed on whether an intervention is beneficial and what
kind of intervention is appropriate. It is crucial to consider
the severity of systemic illness when considering interven-
tion, particularly when considering open arterial surgery.
Because of the severe pulmonary complications associatedPlease cite this article as: Jongkind V et al., Update of the European Society for Vas
Acute Limb Ischaemia in Light of the COVID-19 Pandemic, Based on a Scoping Rev
https://doi.org/10.1016/j.ejvs.2021.08.028with COVID-19, critically ill patients may not be candidates
for any kind of surgical revascularisation; “life before limb”
will be justified in these situations.
There are no high quality data to inform the choice for
open vs. endovascular intervention for COVID-19 associated
ALI. Both have been associated with successful limb salvage,
and both have also been associated with high mortality and
morbidity rates. The choice is probably influenced by spe-
cific anatomical considerations (e.g., presence of athero-
sclerotic plaque, aneurysm), operator preference, and
institutional resources. These observations underline the
importance of Recommendation #13 of the ESVS Guide-
lines:1 that patients diagnosed with ALI are treated in a
vascular centre that offers the full range of open and
endovascular interventions.Open surgical treatment
Open surgical treatment using thromboembolectomy re-
mains the most common revascularisation technique in
many countries and centres. The present review found no
data implying that there is a need to modify the recom-
mendations (15e21) in the Guidelines covering open sur-
gical treatment.1
Because of hypercoagulation status, the risk of minor
amputation following surgical thrombectomy may be higher
than normal, a result of distal microvessel thrombosis.11
Intra-arterial locoregional thrombolysis using alteplase
may be considered as an adjunct to thromboembolectomy,
especially in patients with residual distal thrombus, and foot
ischaemia. In one study of 15 patients, this approach was
used in four of five patients with distal occlusions.44 No
bleeding complications occurred, and limb salvage was
achieved in 14 patients of the entire cohort of 15 patients
(93.3%). Likewise, improved long term results when using
intra-operative intra-arterial thrombolysis in patients with
ALI and popliteal artery aneurysms (who were not COVID-
19þ) were recently reported in a comparative study using
propensity score matching (major adverse limb events 30%
vs. 65%, p < .001).45
To avoid any airway manipulation, regional anaesthesia
might be preferable over general anaesthesia. Benefits of
regional anaesthesia include preservation of respiratory
function, and avoidance of aerosolisation and hence less
viral transmission to staff members.46 This may be espe-
cially important in patients with COVID-19. There is no
scientific evidence to support this theory, although one
cohort series showed that local anaesthesia with sedation
or locoregional anaesthesia was feasible for thromboem-
bolectomy or bypass in 17 patients.44 Recommendation #15
in the ESVS Guidelines states: “For patients requiring sur-
gical thromboembolectomy for acute limb ischaemia,
regional or local anaesthesia may be considered, but always
with an anaesthetist present (Class IIb, Level C)”.1 The au-
thors of this paper agree that this recommendation needs
to be strengthened during the pandemic, and recommendcular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of
iew of the Literature, European Journal of Vascular and Endovascular Surgery,
Table 3. Mortality reported by seven series on >15 patients
infected with COVID-19 and presenting with and / or
receiving intervention for acute limb ischaemia
Author Country Patients e n Mortality e %
Behrendt57 Germany 63 14.1
Bellosta44 USA 20 40
Benson56 19 countries 93 20.4
Etkin19 USA 35 50
Goldman34 USA 16 37.5
Kahlberg25 Italy 41 29.3
Sanchez18 Peru 30 23
6 Vincent Jongkind et al.the preferential use of local or locoregional anaesthesia for
open surgery of ALI in patients with COVID-19.
Endovascular treatment
Thirteen patients were identified, from eight publications,
with catheter directed thrombolysis (CDT) in COVID-19
associated ALI (for details, see Table 2).47e54 Percutaneous
mechanical thrombectomy (PMT) was used (simultaneously)
in some patients. During CDT, continuous heparinisation was
performed in at least four cases.48e50,53 Two reports
described the successful use of thrombolysis or PMT for re-
occlusion after open surgical thrombo-embolectomy.52,54
Since the publication of the 2020 ESVS ALI guidelines,
one important paper has been published describing good
outcomes using PMT in (non-COVID) patients with ALI,
confirming the potential role of percutaneous thrombec-
tomy techniques in the management of ALI.55 Given the
limited resources in ICUs and high dependency units during
the pandemic, any technique reducing the time spent in
critical care constitutes an obvious advantage. These ob-
servations underline the importance of Recommendation
#33 in the ESVS Guidelines,1 stating: “For patients with
acute limb ischaemia, aspiration and mechanical throm-
bectomy should be considered (Grade IIa, Level C)”.
One issue that was studied with particular interest was
whether Recommendation #29 against using continuous
systemic therapeutic heparinisation during thrombolysis
would need to be modified.1 No data were identified from
the literature suggesting this. The specific risks and benefits
of systemic therapeutic heparinisation may be different
from those in non-infected patients, but no data were
identified to support modification of the treatment
algorithms.
Outcomes after treatment
Emerging patterns suggest that the outcomes of patients with
ALI are worse in patients with COVID-19 (Table 3). Imaging
studies in a North American cohort found that the mortalityTable 2. Thrombolysis in 13 patients with acute limb ischaemia an
Author n COVID-19 severity Rutherford stage Tec





Maurera48 1 Mild IIa CD
Muhammad49 1 Mild IIa CD
Vacirca50 1 Severe IIa CD
Horani51 1 Severe IIa CD
Pasqui52 2 Mild IIb CD
Mild IIb PM
Singh53 1 Mild IIa CD
Erkul54 1 Mild IIa CD
CDT ¼ catheter directed thrombolysis; PMT ¼ percutaneous mechanical t
* For re-occlusion after open thromboembolectomy.
y Limb salvage after tibial thromboembolectomy.
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https://doi.org/10.1016/j.ejvs.2021.08.028and amputation rates of patients with ALI were much worse
with simultaneous COVID-19 compared with a propensity
score matched historical control group.34 Adjusted for history
of peripheral arterial disease, death or limb amputation was
more common in patients with COVID-19 (odds ratio 25; 95%
CI 4.3e 147; p< .001). A non-population based international
multicentre study of outcomes after 1 103 open and endo-
vascular interventions for ALI in patients with COVID-19 from
57 centres in 19 countries found mortality of 20.4% in 93 pa-
tients with COVID-19.56
The reasons for worse outcomes may be related to a
reluctance amongst surgeons to operate on ALI in severely ill
patients with COVID-19 infection (perceived futility), late
presentationwith severe ischaemia (there is surprisingly little
evidence for this e see above), and worse outcomes
following the revascularisation itself. In a series from New
York, revascularisationwas performed in only 27% of patients
and primary amputation in 10%.19 The majority of patients
(n ¼ 28, 57%) were treated with systemic anticoagulation,
only three (7%)with systemic tissue plasminogen activator. In
Lombardy, Italy, surgeons highlighted the generally poor
outcomes associated with ALI interventions. In 20 patients
with lower limb ALI, revascularisation was attempted in 17
(85%), but successful in only 12 (71%) patients.44 In an Italian
prospective study of 305 patients referred to four vasculard COVID-19 as reported in eight studies
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Table 4. Topics for future research on COVID-19 and acute
limb ischaemia (ALI)
Theoptimalanticoagulationprophylaxis for patientswithCOVID-19.
The ideal therapeutic anticoagulation strategy and monitoring in
patients with COVID-19 and ALI.
The optimal management strategy for revascularisation, especially
regarding factors associated with poor outcome and choice
between open and endovascular revascularisation.
The potential added value or preferential use of percutaneous
mechanical thrombectomy vs. standard catheter directed
thrombolysis.
The risk of developing ALI during extracorporeal membrane
oxygenation (ECMO) treatment, and preventive strategies
Scoping Review: Acute Limb Ischaemia in Patients with COVID-19 7surgery units during the first wave (March e April 2020), 64
(21%) patients tested positive for COVID-19. In patients with
ALI, the mortality was statistically significantly higher in the
COVID-19 infected group (29.3% vs. 8.9%, p ¼ .014).25 In
Germany, confirmed SARS-CoV-2 infection was associated
with increased mortality in patients with ALI. When
comparing ALI in patients with COVID-19 (2.4%) with those
who were not infected, a higher in hospital mortality was
observed (14.3% vs. 5.0%, p < .001).57
Acute upper limb ischaemia
Most patients presented with lower limb ALI, both before and
during the pandemic. In one multicentre study from Peru,
73.3%of patientspresentingwithALI had lower limb ischaemia
and 26.6% had upper limb ischaemia, which is a higher pro-
portion than expected.18 Other series reported incidences of
5%,44 16.6%,19 20%,58 and 25%11,59 of patients with COVID-19
withALI. In amixed series of 97COVID-19positive andnegative
patients, the proportion of upper limb ischaemia was 10.3%.25
Indes et al. reported a higher upper extremity involvement in
COVID-19 positive patients when compared with COVID-19
negative or not tested patients (20.0% vs. 8.0%).58
The literature regarding patients with COVID-19 and up-
per limb ischaemia consists only of case reports or series,
with a total of 43 reported patients.11,13,14,18,19,25,44,54,58e66
Unfortunately, from the larger series no specific treatment
details or outcomes could be retrieved. Most patients were
treated by surgical thromboembolectomy, a few with
thrombolysis, and for mild ischaemia (often with distal oc-
clusion of the radial and or ulnar artery) conservative
treatment with anticoagulation was performed. In several
papers, in some patients revascularisation was unsuccess-
ful, despite receiving therapeutic dose anticoagulation and
undergoing arterial thromboembolectomy.14,18,54,59 Re-
ported mortality was 25% (six of 24 patients) and major
amputation was required in four surviving patients
(22%).11,13,14,18,44,54,59e66
Post-operative medication and follow up
Very few data were identified regarding post-operative
medication following revascularisation of ALI in patients
with COVID-19. In addition, these are observational studies
with small patient numbers, little detail is given on the type
or dose of anticoagulation, and results seem to be
contradictory.
In a study from Spain of patients who had surgery for
ALI, re-thrombosis occurred in four of six patients, despite
prophylactic or therapeutic anticoagulation.67 In another
study, 11 patients with ALI received anticoagulation ther-
apy initiated before open or endovascular intervention.
The in hospital primary patency rate was 100% and there
were no major amputations in this study.59 Bellosta et al.
evaluated the data from 20 COVID-19þ patients with
ALI.44 Revascularisation was successful in 12 of 17 patients
treated surgically. Although successful revascularisation
was not significantly associated with the post-operative
use of intravenous heparin in this small study, noPlease cite this article as: Jongkind V et al., Update of the European Society for Vas
Acute Limb Ischaemia in Light of the COVID-19 Pandemic, Based on a Scoping Rev
https://doi.org/10.1016/j.ejvs.2021.08.028patient who had received intravenous heparin required re-
intervention. Eight of the 20 patients died in hospital. The
use of a continuous post-operative systemic heparin
infusion was significantly associated with survival (mor-
tality: 0% vs. 57.1%; p ¼ .042). In an Italian study, 15
patients with ALI received post-operative systemic anti-
coagulation with intravenous heparin.68 Re-thrombosis
and amputation occurred in two.
These publications suggest that the use of prolonged
systemic heparin in patients with COVID-19 might improve
surgical treatment efficacy and overall survival. Whether or
not the long term outcome can be improved by specific
anticoagulation or antiplatelet therapy remains to be seen.
In the meantime, it is of great importance to follow Rec-
ommendations #44e48 of the ALI Guidelines.1 Considering
the high percentage of re-thrombosis, it seems particularly
important to perform close and frequent follow up with
physical examination of the patient, and to consider early
re-intervention in case of re-occlusion.
DISCUSSION
This is the first attempt to systematically review the liter-
ature on ALI associated with COVID-19 infection. This re-
view aimed to determine to what extent the current ESVS
recommendations for the management of ALI remain valid,
or need adaptation for this special population.1 Some
changes were identified in the epidemiology of ALI during
the pandemic, affecting younger individuals with fewer
comorbidities, yet suffering worse outcomes compared
with patients without COVID-19.11e15 Elevated D-dimer
levels increase the risk of ALI, and heparin resistance is
more often observed.39e41 Finally, there was no strong
support to change any type of intervention for ALI, other
than organisational aspects minimising the need for ICU
support. Such changes include using local or locoregional
anaesthesia, and endovascular techniques to effect
thrombus clearance.55
This review provided no evidence that initial manage-
ment, including therapeutic heparinisation, hydration, and
supplementary oxygen, should be changed. These may,
however, need to be adjusted to the severity of any pul-
monary injury.
Although a higher dose heparin thromboprophylaxis
would seem appropriate in patients with severe COVID-19,cular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of
iew of the Literature, European Journal of Vascular and Endovascular Surgery,
8 Vincent Jongkind et al.it must be balanced against the individual risk of bleeding;
the results of a large RCT suggest that there is no benefit,
only harm from routine anticoagulation.31 For patients
suffering ALI during the pandemic, treatment should not be
delayed, but isolation measures should be applied until
COVID infection is verified or excluded. For patients with
combined COVID-19 and ALI, extended CTA is advised for
investigation, given the risk of venous and arterial throm-
bosis in multiple locations.
One observation requiring consideration is the low rate
of revascularisation attempts in severely ill patients, and as
a consequence, their high mortality. The relatively good
outcomes observed after revascularisation, despite a higher
risk of re-thrombosis, should be taken into account when
discussing intervention in these patients. After relevant
modifications to the treatment algorithm, there seems to
be no rationale behind denying intervention for patients
with COVID-19 suffering from ALI. Therapeutic anti-
coagulation should be initiated as soon as possible and
revascularisation should be performed promptly for pa-
tients in whom the viability of the limb is threatened
(Rutherford grade IIa or IIb).
The results of this scoping review must be interpreted
with caution, as the large majority of data are observational
and derived from case reports or small case series, which
are inherently biased. It is, however, the best evidence
available to date. It is suggested that healthcare providers
dealing with patients with COVID-19 should make efforts to
collaborate in data collection and sharing, to improve future
management.4
The following aspects were identified as important topics
for future research: 1) the optimal anticoagulation pro-
phylaxis for patients with COVID-19, including dose adap-
tation to the severity of the disease and optimal duration;
2) the ideal therapeutic anticoagulation strategy and
monitoring in patients with COVID-19 and ALI, given the
known predisposition for re-thrombosis and heparin resis-
tance; 3) the optimal management strategy for revascular-
isation, especially regarding factors associated with poor
outcome and choice between open and endovascular
revascularisation; and 4) the potential added value or
preferential use of percutaneous mechanical thrombectomy
vs. standard catheter directed thrombolysis. One issue not
covered by this scoping review is whether patients with
COVID-19 treated with ECMO (ExtraCorporeal Membrane
Oxygenation) develop ALI more often than other ECMO
patients, and whether preventive strategies could reduce
any risk. This is another issue to be covered by future
research efforts (See Table 4).
In conclusion, this scoping review showed that the
epidemiology of ALI has changed, but only slightly. The
recommendations of the ESVS ALI Guidelines remain valid
in the light of the COVID-19 pandemic, although some
minor modifications are suggested. The Guidelines repre-
sent an important aid to clinical practice during the
pandemic.Please cite this article as: Jongkind V et al., Update of the European Society for Vas





APPENDIX A. SUPPLEMENTARY DATA
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.ejvs.2021.08.028.
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